XNAS · Healthcare · Biotechnology
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -1.78 | -1.33 | +25.28% | $0 | ✅ Beat | +2.38% | -0.94% | — |
| 2026-03-04 | Q4 2025 | -1.21 | -0.53 | +56.20% | $0 | ✅ Beat | +1.87% | +2.07% | -12.07% |
| 2025-11-13 |
| Q3 2025 |
| -2.28 |
| -1.41 |
| +38.16% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -3.66 | -3.39 | +7.38% | $0 | ✅ Beat | -0.45% | +1.58% | +14.93% |
| 2025-03-13 | Q4 2024 | -0.35 | -0.01 | +97.14% | $0 | ✅ Beat | +5.34% | +26.87% | -1.70% |
| 2024-11-18 | Q3 2024 | -0.37 | -0.40 | -8.11% | $0 | ❌ Miss | -9.04% | -11.30% | -85.93% |
| 2024-10-29 | Q2 2024 | -1.00 | -0.18 | +82.00% | $0 | ✅ Beat | +0.00% | -0.98% | -24.88% |
| 2024-05-14 | Q1 2024 | -0.72 | -0.74 | -2.78% | $0 | ❌ Miss | +5.66% | +2.20% | +5.66% |
Showing last 8 quarters.